TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
-0.55%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.51B
AUM Growth
+$111M
(+8%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
14.5%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
194
New
40
Increased
63
Reduced
17
Closed
11
Top Buys
| 1 |
Galapagos
GLPG
|
$40.2M |
| 2 |
Relay Therapeutics
RLAY
|
$18.5M |
| 3 |
Replimune Group
REPL
|
$18.2M |
| 4 |
Legend Biotech
LEGN
|
$14.6M |
| 5 |
Immunocore
IMCR
|
$13.3M |
Top Sells
| 1 |
ITOS
iTeos Therapeutics
ITOS
|
$16.8M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$13M |
| 3 |
Immunome
IMNM
|
$10.5M |
| 4 |
ANI Pharmaceuticals
ANIP
|
$7.32M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.4M |
Sector Composition
| 1 | Healthcare | 94.65% |
| 2 | Technology | 1.65% |
| 3 | Communication Services | 1.35% |
| 4 | Consumer Discretionary | 0.56% |
| 5 | Financials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
McDonald's
MCD
$226B
| $975K | 0.06% |
+3,365
| New | +$975K |
|
152
Whirlpool
WHR
$5.07B
| $974K | 0.06% |
+8,510
| New | +$974K |
|
|
KRON
153
DELISTED
Kronos Bio
KRON
| $953K | 0.06% |
+1,003,382
| New | +$953K |
|
154
Sealed Air
SEE
$4.76B
| $952K | 0.06% |
+28,132
| New | +$952K |
|
155
FedEx
FDX
$52.7B
| $942K | 0.06% |
+3,349
| New | +$942K |
|
156
Sherwin-Williams
SHW
$91.5B
| $940K | 0.06% |
2,765
+2,153
| +352% | +$732K |
|
157
Century Therapeutics
IPSC
$40.7M
| $909K | 0.06% |
900,000
| – | – |
|
158
Astria Therapeutics
ATXS
$391M
| $894K | 0.06% |
100,000
| – | – |
|
159
GE Vernova
GEV
$162B
| $891K | 0.06% |
+2,710
| New | +$891K |
|
|
MRNS
160
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $879K | 0.06% |
1,641,945
-3,058,055
| -65% | -$1.64M |
|
161
Kura Oncology
KURA
$706M
| $871K | 0.06% |
100,000
| – | – |
|
162
Chevron
CVX
$321B
| $866K | 0.06% |
+5,978
| New | +$866K |
|
163
Passage Bio
PASG
$22.9M
| $851K | 0.06% |
75,000
| – | – |
|
164
Ford
F
$46.4B
| $849K | 0.06% |
85,749
+72,976
| +571% | +$722K |
|
165
BioAtla
BCAB
$29.1M
| $812K | 0.05% |
1,374,076
+500,000
| +57% | +$296K |
|
166
Enanta Pharmaceuticals
ENTA
$186M
| $728K | 0.05% |
126,655
| – | – |
|
167
Standard BioTools
LAB
$481M
| $714K | 0.05% |
407,755
| – | – |
|
168
MacroGenics
MGNX
$126M
| $711K | 0.05% |
218,856
| – | – |
|
169
Lexicon Pharmaceuticals
LXRX
$378M
| $628K | 0.04% |
850,268
+750,268
| +750% | +$554K |
|
170
Puma Biotechnology
PBYI
$250M
| $610K | 0.04% |
200,000
| – | – |
|
171
NextCure
NXTC
$13M
| $540K | 0.04% |
58,333
+3,967
| +7% | +$36.7K |
|
172
Editas Medicine
EDIT
$219M
| $508K | 0.03% |
+400,000
| New | +$508K |
|
|
ALLK
173
DELISTED
Allakos
ALLK
| $458K | 0.03% |
378,552
+333,290
| +736% | +$403K |
|
174
Amylyx Pharmaceuticals
AMLX
$885M
| $378K | 0.03% |
100,000
| – | – |
|
175
TScan Therapeutics
TCRX
$106M
| $358K | 0.02% |
+117,847
| New | +$358K |
|